 The FDA has approved Aadi Bioscience Incs NASDAQ: AADI Fyarro sirolimus protein-bound particles for injectable suspension albumin-bound for perivascular epithelioid cell tumor PEComa. The approval marks the first and only therapy for adult patients for locally advanced unresectable or metastatic malignant PEComa. 